Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye
- PMID: 29634634
- DOI: 10.1097/CMR.0000000000000443
Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye
Abstract
This report concerns a 49-year-old female with cutaneous malignant melanoma and systemic metastases. These resolved following combination immunotherapy with ipilimumab and nivolumab. She subsequently experienced unilateral floaters, an increase in iris pigmentation and pigmentary glaucoma. The eye progressively lost vision and became painful due to iris neovascularization. The clinical diagnosis was of cutaneous melanoma metastatic to the vitreous, ciliary body and iris. Enucleation was performed for symptom control, with histopathology confirming the clinical diagnosis. The immune privilege of the eye may preclude ocular metastasis control with immunotherapy. Ocular symptoms in such patients merit referral to an ophthalmologist.
Comment in
-
Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases.Melanoma Res. 2019 Jun;29(3):345-347. doi: 10.1097/CMR.0000000000000591. Melanoma Res. 2019. PMID: 31022059 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources